Background: Only one-third of patients with depression respond fully to antidepressant medication
Introduction
Depression is a major public health problem. It is predicted to be the leading cause of disability in high income countries by 2030, with only HIV/AIDS and perinatal conditions ranking higher for low and middle income countries 1 . Antidepressants are often the first-line treatment for depression and prescriptions for such medication have increased dramatically in recent years 2;3 . However, only onethird of patients respond fully to pharmacotherapy and half do not experience at least a 50% reduction in depressive symptoms after 12-14 weeks of medication 4 . Where an adequate dose and duration of treatment has been given, such non-response may be termed 'treatment resistance'.
There is no agreed definition of treatment resistance 5 but, given the extent of non-response, it is clear that treatment resistant depression (TRD) has a substantial impact on individuals, health services and society.
There is no standard approach to the management of TRD. 'Next step' options include increasing the dose of pharmacotherapy, switching to a different antidepressant or augmentation with another pharmacological or psychological treatment. However, there is little robust evidence that these approaches improve outcome 6;7 .
There is good evidence that cognitive behavioural therapy (CBT), the most widely available structured psychotherapy for depression, is effective for previously untreated episodes of depression. There has been some investigation of CBT and its variants in treating chronic and treatment resistant depression. The STAR*D trial evaluated a number of alternative treatment strategies (including switching to, or augmentation with, CBT 8 ) following non-response to medication. However, it did not include a comparison group of patients who continued on their existing medication; hence it is not possible to evaluate the effect of augmenting antidepressant medication with CBT as a 'next step' treatment option from STAR*D. In patients with chronic depression, Keller et al 9 investigated a variant of CBT, cognitive behavioural analysis system of psychotherapy (CBASP) that puts more emphasis on behavioural and interpersonal factors than more traditional CBT. Keller et al 9 found that combined psychotherapy and nefazodone (now withdrawn) was more effective than either component alone. However, a more recent trial of patients with chronic depression that had not responded to antidepressant medication found no difference in response between those who received combined treatment (CBSAP and medication) compared with medication alone 10 .
Limited access to psychological treatment in the UK and elsewhere has meant that, in clinical practice, CBT has often been reserved for those who have not responded to antidepressants. No large-scale randomised controlled trials (RCTs) 6;7 have evaluated the effectiveness of CBT following non-response to pharmacotherapy compared with continuing pharmacotherapy as part of usual care
for patients with TRD..We chose to investigate CBT rather than CBASP as there is evidence that CBT may reduce rates of relapse 11 , including amongst those with residual depressive symptoms 12 .
Furthermore , some models of more persistent depression put emphasis on the cognitive rather than behavioural aspects of treatment 13 .
The aim of the CoBalT trial was to examine the effectiveness of CBT as an adjunct to usual care including pharmacotherapy for primary care patients with treatment resistant depression compared with usual care alone. The economic evaluation will be reported separately.
Methods

Study design
CoBalT was a multi-centre pragmatic RCT with two parallel groups 14 . Ethical approval was given by the West Midlands Research Ethics Committee (NRES/07/H1208/60) and research governance approval was obtained from the local Primary Care Trusts/Health Boards.
Setting and Participants
Participants were recruited from 73 general practices in urban and rural settings in three UK centres:
Bristol, Exeter and Glasgow. Most participants were identified through a search of practice computerised medical records, although general practitioners (GPs) were able to refer patients directly to the research team. The first record search took place in November 2008 and the last patient was randomised in October 2010.
Eligible patients were those aged 18 to 75 years who had adhered 15;16 to an adequate dose (based on the British National Formulary (www.bnf.org.uk/bnf) and advice from psychopharmacology experts (Web Appendix 1)) of antidepressant medication for at least 6 weeks and had a Beck Depression Inventory (BDI) 17 score of 14 or more. They also met ICD-10 criteria for a depressive episode assessed using the revised Clinical Interview Schedule (CIS-R) 18;19 . GPs were asked to exclude patients who: (i) had bipolar disorder, psychosis or major alcohol/substance abuse problems; (ii) were unable to complete the questionnaires; and (iii) were pregnant. Individuals who were currently receiving CBT or other psychotherapy (including counselling) or secondary care for their depression, or who received CBT in the past three years, or who were taking part in another intervention study were also excluded.
Recruitment
A three-stage recruitment process was used 14 . The record search identified patients who had received repeated prescriptions for antidepressants. Those who agreed to be contacted by the research team were mailed a short questionnaire that included questions about their depression and adherence to antidepressants. Those who met the definition of TRD (BDI score ≥14 and adhered to antidepressants at an adequate dose for at least 6 weeks) were contacted by telephone by a researcher to ascertain their eligibility with respect to current/past psychological treatment and current secondary care for depression. Potentially eligible patients were invited to attend a face-toface appointment with a researcher to discuss participating in the trial and confirm their eligibility (BDI score ≥14, continuing to take antidepressants at an adequate dose and fulfilling ICD-10 criteria for depression). Ineligible patients (and those who declined participation) were referred back to their GP.
Randomisation, concealment of allocation and blinding
After the collection of baseline data and obtaining written informed consent for trial participation, eligible patients were randomised to one of two groups: (1) usual care or (2) CBT in addition to usual care. Allocation was stratified by centre and minimised (with a probability weighting of 0. Participants were taking antidepressants at the time of randomisation and were expected to continue with these as part of their usual care from their GP. Treatment allocation was concealed from the researcher through the use of an automated telephone randomisation service that was administered remotely and used a computer-generated code. Given the nature of the intervention it was not possible to blind participants, GPs, CBT therapists or researchers to the treatment allocation.
Intervention and comparator (usual care) groups
Usual care
There were no restrictions on the treatment options for patients randomised to be managed as usual by their GP. Participants could be referred for counselling, CBT or to secondary care, if it was clinically appropriate.
Intervention
Participants received 12 sessions of individual CBT (each lasting 50-60 minutes), with (up to) a further six sessions if judged to be clinically appropriate by the therapist (maximum of 18 sessions)) in addition to usual care from their GP. Therapy took place in the patient's GP surgery or at nearby National Health Service (NHS)/University premises. Therapists used the seminal CBT for depression treatment manuals 21;22 and, where appropriate, elaborations designed to address treatment resistance 13 . Therapists received at least 1 day of training specific to the trial from an experienced CBT therapist (AG) and weekly supervision from experienced CBT supervisors at each centre (GL, WK & CK). Therapists were flexible in responding to problems raised by the patient (e.g. by targeting symptoms of anxiety using appropriate cognitive behavioural models, if these were considered important). Emphasis was also given to formulating the psychopathology in terms of conditional beliefs.
The intervention was delivered by 11 part-time therapists in the three sites who were representative of those working within NHS psychological services 14 . Ten out of the 11 therapists were female, their mean age was 39.2 years (SD 8.1) and they had practised as a therapist for a mean of 9.7 years (range: newly qualified to 30 years).
With patient consent, therapy sessions were audio-recorded. Fidelity of the intervention to the CBT model was evaluated 14 for a random sample of recordings by three independent raters from the Oxford Cognitive Therapy Centre using the Cognitive Therapy Rating scale (CTS-R), a valid and reliable CBT rating scale 23 .
Follow-up
Participants were followed up 3, 6, 9 and 12 months after randomisation 14 . Wherever possible, to maximise retention, researchers met with the participant face-to-face at 6 months and 12 months.
Follow-ups at 3 and 9 months were conducted by telephone. Follow-up data were collected between March 2009 and October 2011.
Outcome measures
The primary outcome was the BDI score at 6 months, specifically a binary variable representing response, defined as a reduction in depressive symptoms of at least 50% compared to baseline.
Secondary outcomes included the BDI score as a continuous variable, remission of symptoms (BDI score of less than 10), and quality of life (SF-12) 24 at 6 and 12 months 14 .
Other secondary outcomes at 6 and 12 months were panic 25 , and measures of depression (PHQ- 9 26 ), and anxiety (GAD- 7 27 ) used in psychological services 28 . Data on use of, and adherence to, antidepressant medication were also collected.
Sample size
The original sample size calculation (using nQuery 5.0) indicated that 472 participants would provide 90% power to detect a difference of 16 percentage points in 'response' between the two groups based on a 2-sided 5% significance level and 15% loss to follow-up at 6 months. This corresponds to an odds ratio of 2, considered clinically important and smaller than that derived from a systematic review of CBT 29 . However, a slightly lower recruitment rate in one centre and difficulty matching recruitment rates to therapist capacity in two centres resulted in a revised sample size target of 432, which had 90% power to detect a 17 percentage point difference (30% versus 47%) in the binary 'response' outcome and 87% power to detect the original difference 14 .
Statistical Analysis
Analysis and reporting of this trial was in accordance with Consolidated Standards of Reporting Trials (CONSORT) guidelines 30 . All analyses were undertaken in Stata 11.2, following a pre-defined analysis plan agreed with the Trial Steering Committee.
Patient characteristics were compared at various stages of study recruitment, including using descriptive statistics to assess the baseline comparability of the randomised groups. The primary comparative analyses between the randomised groups were conducted according to the principle of intention-to-treat (ITT) without imputation of missing data. Logistic regression was used to compare the binary primary outcome at 6 months between the groups as randomised, adjusting for study centre, baseline BDI score and the other three minimisation variables. Secondary analyses used similar regression models with additional adjustment for any variables that demonstrated marked imbalance at baseline and any differences in the actual time to follow-up. The analysis of other secondary outcomes used linear or logistic regression as appropriate, and adjusted for any baseline imbalances. Repeated measures logistic and linear regression models were used to summarise the effect of the intervention on outcomes over 12 months. Odds ratios (OR) or differences in means, 95% confidence intervals (95%CIs) and p values are reported.
Secondary analyses used generalised latent and linear mixed models to obtain a fully specified heteroscedastic model 31 to examine the influence of clustering by therapist. In addition, sensitivity analyses examined the impact of missing data using the method of multiple imputation by chained 
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, interpretation of data, or writing of the paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Participant flow and retention
A detailed description of the recruitment process is outlined in Web Appendix 2 and a summary CONSORT diagram is presented in Figure 1 . In total, 912 patients were identified as having TRD and invited to attend a baseline appointment, but 163 (18%) declined. There were no age or gender differences between those who declined and agreed to attend such an appointment (data not shown), although those who agreed were more highly educated (p=0.009). At baseline, men were more likely to be ineligible (p=0.02) but there were no differences in age or educational background between those who were or were not eligible to participate in the trial (data not shown). Of the 749 who attended a baseline appointment, 63% (n=469) were eligible to participate and gave written informed consent.
Of those randomised, 234 were allocated to receive the intervention and 235 to continue with usual care from their GP. Ninety percent of participants were followed up at 6 months and 84% at 12 months ( Figure 1 ). Older individuals, women, those from higher socio-economic backgrounds, with more social support and better physical function were less likely to have missing BDI outcome data (data not shown). There was some evidence that those who were single, those with more severe depression at baseline, and those who scored more highly on measures of panic were more likely to have missing outcome data (data not shown).
Baseline characteristics of participants
The majority of participants were women (n=339, 72%), the mean age was 49.6 years (SD 11.7) and 44% (n=206) were in paid employment (full/part-time). The mean BDI score at baseline was 31.8 (SD 10.7). Twenty-eight percent (n=129) currently fulfilled ICD-10 criteria for a severe depressive episode and the majority (n=415, 88%) had suffered from depression in the past. The duration of the current episode of depression was 2 years or longer for 59% (n=276) of participants and 70% (n=327) had been on their current antidepressant(s) for more than 12 months. Selective Serotonin Reuptake
Inhibitors (SSRIs) were the most common antidepressant taken at baseline (n =334) (further details are given in Web Appendix 3).
Most participants (n=347) had a secondary diagnosis of an anxiety disorder according to the CIS-R (generalised anxiety: n=245; panic disorder: n=67; phobias: n=35). Forty-three percent (n=202) of participants reported another longstanding illness or disability (diabetes, asthma, arthritis, heart disease, high blood pressure or lung disease).
Amongst those randomised, the intervention group included more men, more individuals in paid employment and more who reported financial difficulty, fewer individuals with caring responsibilities or longstanding illness/disability and better physical function (SF-12) ( Table 1) . A smaller proportion of those in the intervention group had taken their current antidepressants for more than 12 months and they were less likely to have experienced 5 or more prior episodes of depression, although a greater proportion had a family history of depression.
Delivery and receipt of the intervention
Nine of the 11 therapists delivered 97% of the intervention and, for these, the number of patients per therapist ranged from 13 (5.6%) to 41 (17.5%). The mean CTS-R rating (adjusted for caseload)
based on a random sample of 54 sessions was 38.8 (95%CI: 36.7, 40.8) which is above the threshold of competence expected in UK CBT training programmes.
The average duration of the intervention (from randomisation) was 6.3 months (SD 3.0). Twenty participants (8.5%) did not attend any therapy sessions. In total, 74 participants (31.6%) either withdrew from therapy (n=47) or were discharged having repeatedly not attended appointments 
Primary outcome -'response' at 6 months
Those in the intervention group had a three-fold increased odds of 'response' at 6 months compared with those in the usual care group (Table 2) . Adjustment for imbalances at baseline had little effect, if anything slightly increasing the estimated effect, and adjustment for the actual time to follow-up did not affect the findings (data not shown). The difference in proportions 'responding' equated to a number needed to treat (NNT) of 4 (95%CI: 3, 6) for each additional 'responding' patient.
Secondary outcomes at 6 months
The beneficial effect of the intervention was confirmed for the secondary outcomes at 6 months (Table 2) . Those in the intervention group had a BDI score that was, on average, 5.7 points lower (less depressed) than those in the usual care group, which equated to an effect size of 0.53 using baseline SD for BDI (pooled). Those in the intervention group were also more likely to experience 'remission' (BDI score<10) at 6 months (NNT 8 (95%CI: 5, 20)), to have fewer symptoms of anxiety (GAD-7) and panic at 6 months and had greater improvements in the SF-12 mental health subscale (Table 2 ). There was weak evidence that those in the intervention group fared worse on the SF-12 physical subscale, but the difference was small and the 95%CI included the null (Table 2) .
Adjustment for baseline imbalances did not affect any of these findings (data not shown).
Secondary analyses for the primary outcome
There was little evidence of clustering of outcomes by therapist (intracluster correlation coefficient for continuous BDI score, after adjustment for baseline, was 0.0027). In a fully heteroscedastic model that accounted for clustering by therapist, the results obtained for the primary 'response' outcome were identical to those obtained from the primary ITT analysis (data not shown). The results imputing missing data were consistent with the findings of the primary 'complete-case' analysis (Table 3) . Regarding a priori subgroup analyses, there was no evidence that patient expectation of outcome or degree of treatment resistance had any effect on the difference between intervention and usual care groups (p value for interaction: 0.16 and 0.88 respectively). In a post-hoc sub-group analysis, there was no evidence that study centre had any effect on the difference between the intervention and usual care groups (p value for interaction between treatment allocation and centre: 0.61).
Outcomes over 12 months
In repeated measures analyses using data from 6 and 12 months, those in the intervention group had a three-fold increased odds of response and remission over the 12 months (Table 4 ). There was little evidence that the effect of the intervention varied over time (p value for interactions >0.10), with the exception of the outcomes on the PHQ-9 and SF-12 physical sub-scale where there was weak evidence for an interaction (p =0.059 and p=0.047 respectively).
Treatment efficacy
Compared with the ITT models in Table 2 , the estimates of treatment efficacy obtained from CACE analyses demonstrated that the effect of the intervention was larger amongst those who were 'on track' at 6 months to complete the intervention, and likewise among those who received at least 12 sessions by 12 months. At 6 months the CACE estimate for the continuous BDI outcome was -8.2
(95%CI: -11.4, -5.0), and at 12 months -7.1 (95%CI: -10.4, -3.8) (effect size 0.77 and 0.66 respectively; both p<0.001). Larger effects were also observed for the binary outcomes using probit regression (data not shown).
Of 388 participants with data at 6 and 12 months, 66 participants (17%) had at least one session of 'talking therapy' outwith the trial during the 12 months (usual care: n = 41 (21.0%); intervention: 25 Of those taking antidepressants at 6 months, 92% of the intervention group and 88% of those in usual care had adhered to their medication over the previous 6 weeks. The comparable figure at 12 months for both groups was 93%.
Discussion
CBT as an adjunct to usual care that included pharmacotherapy was effective in reducing depressive symptoms and improving quality of life in primary care patients with TRD. The beneficial effect of the intervention was also observed for the more stringent criteria of 'remission' and improvements were maintained over 12 months.
There is no single accepted definition of TRD, hence we used an inclusive and pragmatic definition that would be generalisable to primary care 33 . Participants had not responded to at least 6 weeks treatment with an antidepressant; however, this was a heterogeneous group with many reporting chronic depression often associated with psychological and/or physical co-morbidities. The mean BDI score was 31.8, 29% of participants had severe depression at baseline according to ICD-10 criteria, and most had a past history of depression, with the majority reporting at least five previous episodes. Hence, we think that the results are generalisable to a wide range of patients who have not responded to antidepressants.
Prior to this study, there was no evidence from large-scale RCTs on the effectiveness of CBT as an adjunct to pharmacotherapy as a 'next step' treatment option for primary care patients who had not responded to antidepressants 6;7 . Recent trials (including our pilot 34 ) were small (n<50) 35;36 . In the STAR*D study , only 26% of participants were willing to be randomised to CBT as a second-step option 8 In the REVAMP trial, a treatment algorithm was used and pharmacotherapy changed to the 'nextstep' following randomisation 10 . However, the use of a medication algorithm is not a pragmatic approach towards pharmacotherapy. There was a higher remission rate amongst those receiving pharmacotherapy in REVAMP (38.5% at 12 weeks) compared with CoBalT (15.0% for the usual care group at 6 months), but this may relate to differences in the patients recruited. Only 33% of REVAMP participants had previously had an adequate trial of pharmacotherapy, whereas 80% of CoBalT participants had previously been prescribed antidepressants and most (70%) had been on their current medication for more than 12 months.
Strengths and limitations of the study
This was a large study with high follow-up rates at 6 and 12 months. There was no evidence that missing data had biased findings. Though there were some imbalances in baseline characteristics, between the randomised groups, if anything, adjusting for these increased the size of the treatment effect for the primary outcome. Only a minority of participants received CBT outwith the trial so such contamination had little impact on the findings.
We did not compare CBT with an "attention" control as we wanted to ask a pragmatic question about the value of adding CBT to antidepressants in this population. This meant we could not blind patients or researchers to the treatment allocation but we avoided observer bias by using self-report questionnaires to measure outcome. Our primary outcome was depressive symptoms on the BDI.
This instrument was also used by the therapists within CBT sessions; hence, for those in the intervention group, the responses on this specific measure may have been influenced by the process of therapy. However, results were consistent for the other mental health outcomes (that were not used in therapy), including for the PHQ-9, which is part of the core outcome dataset within UK psychological services 28 .
An independent evaluation confirmed that the therapy was delivered at a 'competent' 23 standard.
The therapists were broadly representative of those working in NHS psychological services with a range of experience and backgrounds and thus the results should therefore be generalisable. There was no evidence of any clustering of outcomes by therapist.
We relied on a self-report measure of adherence to medication 15 that had been validated against electronic monitoring bottles 16 in order to define our population with TRD. Whilst some of those recruited may not have adhered to their medication ('false positives'), the vast majority had, at baseline, been on their current antidepressant for more than 12 months, which is likely to minimise the effect of occasional non-adherence.
Implications for practice and directions for future research
A substantial proportion of people do not respond to antidepressants and our results have provided robust evidence that CBT given as an adjunct to usual care that includes antidepressant medication is an effective treatment in reducing depressive symptoms and improving quality of life in this population. The size of the treatment response was substantial and of clinical importance and was maintained at the 12 month follow-up after the CBT treatment had ended. Given the chronic relapsing nature of depression, it would be important to examine the long-term outcome of this intervention.
Though we did not test different approaches towards the delivery of CBT we think that the complex mental health needs of this population require therapists who are able to tailor the treatment approach to the individual and formulate conditional beliefs that, according to cognitive theory 13;21 , underpin the longer term risk of depression. This kind of therapy would be delivered by "high intensity" services in England 28 (http://www.iapt.nhs.uk/) and requires both training and regular supervision.
In many countries, access to psychological treatment is limited to those who can afford to pay, or those with health insurance, and amongst the latter, cost-sharing through co-payment is common.
Increasing the availability of CBT is more difficult than providing an intervention such as pharmacotherapy. There have been recent initiatives to increase access to psychological therapies in . Even those who attend therapy often receive an "eclectic mix of psychotherapy techniques" 39 rather than CBT. Only through greater investment in psychological services that deliver evidence-based therapies will it be possible to reduce the significant burden to patients, health care systems and society that is associated with non-response to the most common first-line treatment for depression in primary care.
Panel: Research in context Systematic Review
Systematic reviews of psychological interventions for treatment resistant depression have found no large-scale high quality trials of CBT as an adjunct to pharmacotherapy as a 'next step' treatment option compared with continuing pharmacotherapy as part of usual care 6;7 . Using search terms based on these reviews, we identified three trials that have been published subsequently. One of which was our pilot study (n=25) for this RCT 34 , the second (n=44) examined augmentation with CBT amongst partial responders to antidepressants 35 and the third study (n=36) of inpatients was published only as a conference abstract 36 . Neither of the latter two studies included a group who remained on antidepressants in order to evaluate the effectiveness of CBT as an adjunct to antidepressant medication (comparators: lithium augmentation 35 ; and augmentation with supportive therapy 36 ).
Interpretation
The results of this large-scale multi-centre trial are useful in informing the 'next step' treatment for those who do not respond to antidepressant medication. CBT given as an adjunct to usual care that included antidepressant medication was found to be an effective treatment in reducing depressive symptoms and improving quality of life over 12 months compared with usual care alone for primary care patients with treatment resistant depression. Incomplete data on some items, numbers with information available as listed: *CBT n = 232, UC n = 231; † CBT n = 233, UC n = 235; ‡ CBT n = 231, UC n = 233 
